Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Verna Welch"'
Autor:
Charles H. Jones, John R. Androsavich, Nina So, Matthew P. Jenkins, Derek MacCormack, Andrew Prigodich, Verna Welch, Jane M. True, Mikael Dolsten
Publikováno v:
npj Genomic Medicine, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract In the past decade, RNA therapeutics have gone from being a promising concept to one of the most exciting frontiers in healthcare and pharmaceuticals. The field is now entering what many call a renaissance or “RNAissance” which is being
Externí odkaz:
https://doaj.org/article/29d29f5f45c04de3b82b3bce6a3a0711
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract The COVID-19 pandemic was met with rapid, unprecedented global collaboration and action. Even still, the public health, societal, and economic impact may be felt for years to come. The risk of another pandemic occurring in the next few decad
Externí odkaz:
https://doaj.org/article/990527f051604d86b3bc9bef5a854f56
Autor:
David MARKS, Marcos DE LIMA, Partow KEBRIAEI, Francesco LANZA, Christina CHO, Sergio GIRALT, Gizelle POPRADI, Michael HEMMER, Wael SABER, Xin ZHANG, Richa SHAH, Verna WELCH, Erik VANDENDRIES, Matthias STELLJES
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S34- (2021)
Objective: InO is a CD22-directed antibody-drug conjugate indicated for treatment of relapsed/refractory (R/R) ALL. InO has been associated with hepatotoxicity and hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), particularly
Externí odkaz:
https://doaj.org/article/f431a58aacfd4959a47594143e1bfe9f
Autor:
David I. Marks, Ilse vanOostrum, Sabrina Mueller, Verna Welch, Erik Vandendries, Fausto R. Loberiza, Sarah Böhme, Yun Su, Matthias Stelljes, Hagop M. Kantarjian
Publikováno v:
Cancer Medicine, Vol 8, Iss 13, Pp 5959-5968 (2019)
Abstract Background Inotuzumab Ozogamicin (INO), has demonstrated an improvement in overall survival, high rate of complete remission, favorable patient‐reported outcomes, and manageable safety profile vs standard of care (SoC; intensive chemothera
Externí odkaz:
https://doaj.org/article/a2a35faf2f194dc2a27b3c36598f418a
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Autor:
Thomas W. LeBlanc, Nigel H. Russell, Loriana Hernandez-Aldama, Charlotte Panter, Timothy J. Bell, Verna Welch, Diana Merino Vega, Louise O’Hara, Julia Stein, Melissa Barclay, Francois Peloquin, Andrew Brown, Jasmine Healy, Lucy Morgan, Adam Gater, Ryan Hohman, Karim Amer, Dawn Maze, Roland B. Walter
Publikováno v:
Oncology and Therapy. 10:421-440
Treatment decisions in older adults with acute myeloid leukemia (AML) are challenging, particularly for those who are not candidates for intensive chemotherapy (IC), and the trade-offs patients, their families and physicians consider when choosing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b6e9d8f8d97437e13111c0f43e38e99
https://doi.org/10.1007/s40487-022-00200-9
https://doi.org/10.1007/s40487-022-00200-9
Autor:
Jakob Langer, Verna Welch, Mary Moran, Alejandro Cane, Santiago Lopez, Amit Srivastava, Ashley Enstone, Amy Sears, Kristen Markus, Maria Heuser, Rachel Kewley, Isabelle Whittle
Introduction: Adults aged ≥65 years contribute a large proportion of influenza-related hospitalizations and deaths due to increased risk of complications, which result in high medical costs and reduced health-related quality of life (HRQoL). Althou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::971cf13d3bdc3625afa6c9d9c88816cc
https://doi.org/10.22541/au.168197073.31574682/v1
https://doi.org/10.22541/au.168197073.31574682/v1
Autor:
Marcos J.G. de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi, Michael T Hemmer, Mei-Jie Zhang, Fan Zhang, Richa Shah, Verna Welch, Saara Tikka, Erik Vandendries, Matthias Stelljes, David I. Marks, Wael Saber
Publikováno v:
Blood. 140:6023-6025
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a2213903f85e00bc594d268ba0982d0
https://doi.org/10.1182/blood-2022-160315
https://doi.org/10.1182/blood-2022-160315
Autor:
Alison Booth, Timothy Bell, Sonia Halhol, Shiyu Pan, Verna Welch, Evie Merinopoulou, Dimitra Lambrelli, Andrew Cox
BACKGROUND Until recently, treatment options were limited for patients with acute myeloid leukemia and myelodysplastic syndrome (AML and MDS) who are ineligible for intensive chemotherapy. Owing to the condition’s rapid progression, it is difficult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e25741e4c82525be57ee5cdd84f50b3
https://doi.org/10.2196/preprints.14285
https://doi.org/10.2196/preprints.14285
Autor:
Lance S Longmore, Kimberly J Reid, Mikhail Kosiborod, Frederick A Masoudi, Verna Welch, Alpesh A Amin, John A Spertus
Publikováno v:
Circulation. 118
While diabetes is known to be associated with increased mortality after MI, whether these differences in outcome are due to patient characteristics, treatment, or other biological factors is unknown. We analyzed a contemporary cohort of MI survivors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e11da912dab90328734b78e9064b27c
https://doi.org/10.1161/circ.118.suppl_18.s_1164-a
https://doi.org/10.1161/circ.118.suppl_18.s_1164-a